Sarah E. Pinder

41.6k total citations
328 papers, 15.0k citations indexed

About

Sarah E. Pinder is a scholar working on Cancer Research, Pathology and Forensic Medicine and Oncology. According to data from OpenAlex, Sarah E. Pinder has authored 328 papers receiving a total of 15.0k indexed citations (citations by other indexed papers that have themselves been cited), including 205 papers in Cancer Research, 150 papers in Pathology and Forensic Medicine and 130 papers in Oncology. Recurrent topics in Sarah E. Pinder's work include Breast Cancer Treatment Studies (183 papers), Breast Lesions and Carcinomas (142 papers) and HER2/EGFR in Cancer Research (45 papers). Sarah E. Pinder is often cited by papers focused on Breast Cancer Treatment Studies (183 papers), Breast Lesions and Carcinomas (142 papers) and HER2/EGFR in Cancer Research (45 papers). Sarah E. Pinder collaborates with scholars based in United Kingdom, United States and Australia. Sarah E. Pinder's co-authors include Ian O. Ellis, J.F.R. Robertson, Carlos Caldas, R.W. Blamey, Arnie Purushotham, Elena Provenzano, C.W. Elston, Claire E. Paish, Dalia M. Abd El‐Rehim and Andrew Evans and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Sarah E. Pinder

320 papers receiving 14.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sarah E. Pinder United Kingdom	67	7.3k	6.6k	4.6k	3.9k	2.0k	328	15.0k
Sunil R. Lakhani Australia	71	8.2k 1.1×	7.1k 1.1×	5.0k 1.1×	6.8k 1.8×	1.8k 0.9×	302	18.7k
James L. Connolly United States	63	8.7k 1.2×	5.0k 0.8×	6.6k 1.4×	1.9k 0.5×	1.8k 0.9×	197	14.2k
Wedad Hanna Canada	45	7.6k 1.0×	10.6k 1.6×	2.7k 0.6×	4.6k 1.2×	3.5k 1.7×	156	17.0k
Savitri Krishnamurthy United States	59	6.1k 0.8×	5.0k 0.8×	3.8k 0.8×	2.4k 0.6×	1.1k 0.5×	277	11.9k
Britta Weigelt United States	70	8.4k 1.2×	8.1k 1.2×	3.5k 0.8×	7.8k 2.0×	1.2k 0.6×	311	19.1k
P. J. van Diest Netherlands	75	8.8k 1.2×	8.3k 1.3×	5.0k 1.1×	7.5k 1.9×	4.0k 1.9×	669	25.4k
Ayşegül A. Şahin United States	87	10.2k 1.4×	12.1k 1.8×	5.7k 1.2×	9.0k 2.3×	3.1k 1.5×	389	25.3k
Lynn C. Hartmann United States	59	4.4k 0.6×	4.9k 0.7×	2.9k 0.6×	3.2k 0.8×	828 0.4×	203	13.0k
Fernando Schmitt Portugal	60	4.4k 0.6×	5.3k 0.8×	2.1k 0.5×	5.5k 1.4×	798 0.4×	315	13.0k
Emiel J. Rutgers Netherlands	73	13.1k 1.8×	8.2k 1.3×	7.3k 1.6×	2.6k 0.7×	3.7k 1.8×	467	21.4k

Countries citing papers authored by Sarah E. Pinder

Since Specialization

Citations

This map shows the geographic impact of Sarah E. Pinder's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah E. Pinder with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah E. Pinder more than expected).

Fields of papers citing papers by Sarah E. Pinder

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah E. Pinder. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah E. Pinder. The network helps show where Sarah E. Pinder may publish in the future.

Co-authorship network of co-authors of Sarah E. Pinder

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah E. Pinder. A scholar is included among the top collaborators of Sarah E. Pinder based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah E. Pinder. Sarah E. Pinder is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lips, Esther H., Lennart Mulder, Elinor J. Sawyer, et al.. (2025). Deep learning for predicting invasive recurrence of ductal carcinoma in situ: leveraging histopathology images and clinical features. EBioMedicine. 116. 105750–105750. 1 indexed citations

Lyburn, Iain, Sarah E. Pinder, R.A. Scott, et al.. (2023). Exploration of utility of combined optical photothermal infrared and Raman imaging for investigating the chemical composition of microcalcifications in breast cancer. Analytical Methods. 15(13). 1620–1630. 13 indexed citations

Tovey, Holly, Joel S. Parker, Katherine A. Hoadley, et al.. (2023). Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727). Clinical Cancer Research. 29(18). 3691–3705. 3 indexed citations

Maxwell, Anthony, Bridget Hilton, Karen Clements, et al.. (2022). Unresected screen-detected ductal carcinoma in situ: Outcomes of 311 women in the Forget-Me-Not 2 study. The Breast. 61. 145–155. 21 indexed citations

Provenzano, Elena, Rahul Deb, Susan Pritchard, et al.. (2021). Impact of COVID-19 on the practice of breast pathologists: a survey of breast pathologists in the UK and Ireland. Journal of Clinical Pathology. 76(4). 234–238. 3 indexed citations

Opzoomer, James W., Joanne E. Anstee, Isaac Dean, et al.. (2021). Macrophages orchestrate the expansion of a proangiogenic perivascular niche during cancer progression. Science Advances. 7(45). eabg9518–eabg9518. 56 indexed citations

Thorat, Mangesh A., J. Louise Jones, Sarah E. Pinder, et al.. (2021). Prognostic and Predictive Value of HER2 Expression in Ductal Carcinoma In Situ : Results from the UK/ANZ DCIS Randomized Trial. Clinical Cancer Research. 27(19). 5317–5324. 27 indexed citations

Thorat, Mangesh A., J. Louise Jones, Sarah E. Pinder, et al.. (2021). Prognostic Value of ER and PgR Expression and the Impact of Multi-clonal Expression for Recurrence in Ductal Carcinoma in situ : Results from the UK/ANZ DCIS Trial. Clinical Cancer Research. 27(10). 2861–2867. 10 indexed citations

Rakha, Emad A., Cecily Quinn, Maria Pia Foschini, et al.. (2020). Metaplastic carcinomas of the breast without evidence of epithelial differentiation: a diagnostic approach for management. Histopathology. 78(5). 759–771. 14 indexed citations

10.

Beatson, Richard, Rosalind Graham, Domenico Cozzetto, et al.. (2020). Cancer-associated hypersialylated MUC1 drives the differentiation of human monocytes into macrophages with a pathogenic phenotype. Communications Biology. 3(1). 644–644. 50 indexed citations

11.

Rakha, Emad A., et al.. (2018). Diagnostic concordance of reporting lymphovascular invasion in breast cancer. Journal of Clinical Pathology. 71(9). 802–805. 18 indexed citations

12.

Grigoriadis, Anita, Patrycja Gazińska, Trupti Pai, et al.. (2018). Histological scoring of immune and stromal features in breast and axillary lymph nodes is prognostic for distant metastasis in lymph node‐positive breast cancers. The Journal of Pathology Clinical Research. 4(1). 39–54. 20 indexed citations

13.

Lawler, Katherine, Efterpi Papouli, Cristina Naceur‐Lombardelli, et al.. (2017). Gene expression modules in primary breast cancers as risk factors for organotropic patterns of first metastatic spread: a case control study. Breast Cancer Research. 19(1). 113–113. 4 indexed citations

14.

Abdel-Fatah, Tarek M., Graham Ball, Andrew H.S. Lee, et al.. (2014). Nottingham Clinico-Pathological Response Index (NPRI) after Neoadjuvant Chemotherapy (Neo-ACT) Accurately Predicts Clinical Outcome in Locally Advanced Breast Cancer. Clinical Cancer Research. 21(5). 1052–1062. 14 indexed citations

15.

Anninga, Bauke, Munir Ahmed, Raluca M. Fratila, et al.. (2013). Lymphatic mapping and sentinel lymph node biopsy in an in-vivo porcine model using a novel magnetic technique. European Journal of Cancer. 49. 1 indexed citations

16.

Gazińska, Patrycja, Anita Grigoriadis, John P. Brown, et al.. (2013). Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles. Modern Pathology. 26(7). 955–966. 67 indexed citations

17.

Julien, Sylvain, Aleksandar Ívetic, Anita Grigoriadis, et al.. (2011). Selectin Ligand Sialyl-Lewis x Antigen Drives Metastasis of Hormone-Dependent Breast Cancers. Cancer Research. 71(24). 7683–7693. 156 indexed citations

18.

Simpson, Peter T., Jorge S. Reis‐Filho, Chris Jones, et al.. (2005). Columnar Cell Lesions of the Breast: The Missing Link in Breast Cancer Progression?. The American Journal of Surgical Pathology. 29(6). 734–746. 200 indexed citations

19.

Burrell, H.C., Andrew Evans, A.R.M. Wilson, & Sarah E. Pinder. (2001). False-negative Breast Screening Assessment. What Lessons Can We Learn?. Clinical Radiology. 56(5). 385–388. 52 indexed citations

20.

Badve, Sunil, Roger A’Hern, Rosemary R. Millis, et al.. (1998). Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: A comparative study with long follow-up. Human Pathology. 29(9). 915–923. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact